CONMED Corp. 10-Q Summary: Quarter Ended June 30, 2005
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 2005, and the six-month period ended on that date. CONMED Corporation is a medical technology company specializing in instruments, implants, and video equipment for arthroscopic sports medicine, powered surgical instruments, electrosurgery systems, endosurgery products, and patient care products. The company operates through five principal units aggregated into a single segment. A significant portion of revenue (37.6% for the six months) is derived from international sales.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2005 | Six Months Ended June 30, 2005 |
|---|---|---|
| Net Sales | $158.3 million | $314.1 million |
| Gross Profit | $82.1 million (51.9% margin) | $162.6 million (51.8% margin) |
| Net Income | $10.5 million | $21.3 million |
| Diluted EPS | $0.35 | $0.71 |
| Operating Cash Flow (6mo) | $29.9 million | |
| Total Debt (Long-term + Current) | $273.5 million | |
| Cash and Equivalents | $6.5 million |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 20.9% ($27.4 million) for the quarter and 18.6% ($49.2 million) for the six months compared to the prior year. The Bard Endoscopic Technologies acquisition accounted for $15.0 million of the quarterly increase and $29.2 million of the six-month increase. Favorable foreign currency exchange rates contributed an additional $1.9 million (quarter) and $3.7 million (six months).
- Profitability Decline: Despite revenue growth, Net Income decreased 14.5% for the quarter and 12.6% for the six months. Operating income dropped from $21.5 million to $19.6 million (quarter) and from $43.3 million to $39.8 million (six months).
- Margin Compression: Gross profit margins declined from 52.5% to 51.9% (quarter) and 52.5% to 51.8% (six months). This was primarily due to $1.8 million (quarter) and $4.2 million (six months) in acquisition-related charges included in cost of sales, specifically inventory step-up costs and transition expenses from the Bard acquisition.
- Expense Increases: Selling and administrative expenses rose to 33.8% of sales (from 32.4% prior year quarter) due to litigation costs against Johnson & Johnson, Bard acquisition integration, and higher petroleum prices. R&D expenses increased to 4.0% of sales (from 3.7%) due to the Bard acquisition.
- Other Expenses: The company recorded $2.6 million in "Other expense" for the quarter (none in prior year), comprising $0.7 million for an environmental settlement, $0.4 million for a terminated product line (surgical lights), and $1.4 million in Bard acquisition integration costs.
Guidance, Outlook, and Risks
- Acquisition Integration: The transition of Bard Endoscopic Technologies manufacturing from C.R. Bard facilities to CONMED facilities is underway and expected to be completed in 2006. Management expects costs associated with this transition to decrease once complete.
- Capital Expenditures: Capital spending was $8.1 million for the six months ended June 30, 2005. Management expects total capital expenditures to approximate $15.0 million for the full year 2005.
- Stock Repurchases: The company repurchased $7.8 million of common stock in the first half of 2005 under a $50.0 million program. Management plans to repurchase an additional $5.0 million in the third quarter to offset dilution from employee stock plans.
- Legal Proceedings: CONMED is engaged in antitrust litigation against Johnson & Johnson regarding endoscopic surgery products. While management believes the claims are well-grounded, there is no assurance of success, and costs may be material.
- Environmental Liability: The company settled environmental claims related to a former subsidiary's operations in the 1980s for approximately $0.7 million.
- Accounting Changes: The company is evaluating the impact of SFAS 123R (Share-Based Payment), required to be adopted by January 1, 2006, which will likely increase reported expenses.
Investor Verification Checklist
- Acquisition Synergies: Verify the timeline and cost savings associated with the Bard Endoscopic Technologies manufacturing transition expected to complete in 2006.
- Legal Exposure: Monitor the status and potential cost impact of the antitrust lawsuit against Johnson & Johnson.
- Inventory Levels: Review inventory balances ($142.1 million at June 30, 2005) given the $18.6 million increase in inventory during the six-month period to support the Bard transition.
- Debt Service: Confirm the company's ability to service $273.5 million in debt, including the 2.50% convertible notes and senior credit facility, amidst margin pressure.
- Stock-Based Compensation: Assess the potential impact of adopting SFAS 123R on future earnings per share, as pro forma figures currently show a reduction in net income.